Fusen Pharmaceutical Balance Sheet Health
Financial Health criteria checks 1/6
Fusen Pharmaceutical has a total shareholder equity of CN¥519.2M and total debt of CN¥347.9M, which brings its debt-to-equity ratio to 67%. Its total assets and total liabilities are CN¥1.3B and CN¥818.2M respectively.
Key information
67.0%
Debt to equity ratio
CN¥347.94m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.82m |
| Equity | CN¥519.16m |
| Total liabilities | CN¥818.21m |
| Total assets | CN¥1.34b |
Recent financial health updates
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28Recent updates
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price
Dec 18Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20Financial Position Analysis
Short Term Liabilities: 1652's short term assets (CN¥504.2M) do not cover its short term liabilities (CN¥690.8M).
Long Term Liabilities: 1652's short term assets (CN¥504.2M) exceed its long term liabilities (CN¥127.4M).
Debt to Equity History and Analysis
Debt Level: 1652's net debt to equity ratio (66.5%) is considered high.
Reducing Debt: 1652's debt to equity ratio has increased from 26.6% to 67% over the past 5 years.
Debt Coverage: 1652's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 1652's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:03 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fusen Pharmaceutical Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|